Skip to main content

Table 1 Biomarker levels at baseline and week 4

From: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Plasma Biomarker

Cabozantinib

N = 330

Everolimus

N = 328

Baseline Level

Fold Change at week 4

p-value

Baseline Level

Fold Change at week 4

p-value

Median

Median

Mean

Median

Median

Mean

CA9

77.92

1.93

4.84

< 0.0001

87.49

1.15

2.60

< 0.0001

HGF

745.0

0.86

1.09

< 0.0001

721.1

1.09

1.51

0.002

MET

182.8

1.09

1.13

< 0.0001

178.0

0.98

1.00

0.05

GAS6

14,760

1.40

1.51

< 0.0001

14,570

1.12

1.11

< 0.0001

AXL

14,820

1.14

1.20

< 0.0001

14,690

0.92

0.94

< 0.0001

VEGF

11.55

2.57

6.74

< 0.0001

11.20

1.11

3.65

0.005

VEGFR2

4699

0.79

0.85

< 0.0001

4918

0.84

0.89

< 0.0001

IL-8

4.601

1.23

3.44

0.004

5.049

1.32

6.46

< 0.0001

  1. All values in pg/mL except for MET which is in ng/mL
  2. Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus arm, respectively, with the exception of IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us